Gerresheimer stock rises 5.09 percent to EUR 30.16, 5.75 percent below high

Published on 10/16/2026 at 16:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 578 million on September 30, 2026. Gerresheimer stock costs EUR 30.16 on October 16, 2026, up 5.09 percent versus the Xetra close.

Price action and valuation

Gerresheimer stock rose 5.09 percent on October 16, 2026.
Second-quarter revenue reached EUR 578 million, while adjusted EBITDA came to EUR 102 million.
Gerresheimer stock cost EUR 30.16 at Lang & Schwarz on October 16, 2026 at 4:01 p.m. CEST, 5.09 percent above the Xetra close of October 15, 2026.
LBBW raised its target from EUR 28.00 to EUR 29.00 on October 6, 2026.

Architektur-Rendering einer modernen Pharmaverpackungs-Produktionsanlage — Gerresheimer AG, ISIN DE000A0LD6E6, betreibt moderne Produktionsanlagen mit zeitgemäßer Architektur für Glas- und Kunststoffverpackungen weltweit, Illustration mit AI erstellt.

Gerresheimer stock rose 5.09 percent above the Xetra close on October 16, 2026, putting the price 5.75 percent below its 52-week high. Gerresheimer was trading at EUR 30.16 at Lang & Schwarz on October 16, 2026 at 4:01 p.m. CEST, up 5.09 percent versus the Xetra close of October 15, 2026 (EUR 28.70).

Second-quarter figures improve sequentially

FT.com reported on September 30, 2026 that Gerresheimer generated EUR 578 million in revenue in the second quarter of 2026, down from EUR 614 million in the year-ago quarter. Adjusted EBITDA reached EUR 102 million, versus EUR 126 million a year earlier and EUR 67 million in the first quarter, while the adjusted EBITDA margin improved to 17.6 percent.

For the first half of 2026, revenue totaled EUR 1.10 billion, compared with EUR 1.14 billion in the first half of 2025. Adjusted EBITDA came to EUR 168 million, down from EUR 224 million in the prior-year period. The figures show a sharper sequential recovery alongside a weaker year-over-year comparison.

Stock remains below its yearly high

The 52-week range extends from EUR 14.83 to EUR 32.00. At EUR 30.16, the stock stood 5.75 percent below the high and 103.44 percent above the low on October 16, 2026. Trading volume reached 175,141 shares against an average of 151,709 shares, while the bid was EUR 30.10 and the ask EUR 30.22.

Target stays below the market price

On October 6, 2026, Goldesel reported that LBBW raised its Gerresheimer target from EUR 28.00 to EUR 29.00 and kept a Hold rating. The new target lies 3.85 percent below the Lang & Schwarz price. Gerresheimer's market capitalization was EUR 1.0 billion, and its price-to-earnings ratio was minus 2.59 as of October 16, 2026.

Comparison with peers

Gerresheimer (Xetra, EUR): plus 5.09 percent, P/E minus 2.59, market capitalization EUR 1.0 billion.

SCHOTT Pharma (Frankfurt, EUR): plus 0.20 percent, P/E 27.03, market capitalization EUR 3.7 billion.

Stevanato Group (Nasdaq, USD): minus 0.52 percent, P/E 35.44, market capitalization USD 5.2 billion.

Price and investor context

The October 16 move placed Gerresheimer near the upper end of its annual range, while the LBBW target remained below the market price. The next valuation signal will come from the company's earnings development after the first-half recovery.

Gerresheimer was trading at EUR 30.16 at Lang & Schwarz on October 16, 2026 at 4:01 p.m. CEST, up 5.09 percent versus the Xetra close of October 15, 2026 (EUR 28.70). The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.